AI Eye Podcast 698: Stocks discussed: (NYSE: GWRE) (ASX: BRN)


Vancouver, Kelowna, Delta, BC – May 23, 2022 ( Newswire), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye watching stock news, deal tracker and advancements in artificial intelligence.

Listen to today’s podcast:

AI Eye Podcast 698: Stocks discussed: (NYSE: GWRE) (ASX: BRN)

May 23, 2022


Hear the AI Eye on Spotify

Today’s Column – The AI Eye – Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (NYSE:GWRE) (ASX:BRN)

Private firm Gradient AI, an enterprise software provider of AI solutions for the insurance industry, has announced that it has joined the Insurtech Vanguards program led by tech firm Guidewire Software, Inc. (NYSE:GWRE). According to the press release, Insurtech Vanguards is “a community of select startups and technology providers that are bringing novel solutions to the P&C industry,” wherein Gradient AI will “help insurers learn about the newest insurtechs and how to best leverage them.” Laura Drabik, Guidewire’s chief evangelist, commented:

“Gradient AI is an effective, innovative, and proven insurance solution providing insurers the intelligence needed to significantly improve their efficiency and profitability in claims and underwriting operations. We are thrilled to welcome Gradient AI as part of our program so our mutual customers can harness the powerful benefits of AI and its competitive advantages in pricing, underwriting, and claims management.”

BrainChip Holdings Ltd. (ASX:BRN) has been accepted into the Arm AI Partner Program, described as “an ecosystem of hardware and software specialists enabling developers to deliver the next generation of AI solutions.” Joining the Arm Program allows BrainChip to build out its own ecosystem for Akida, the company’s neuromorphic processor. Jerome Nadel, BrainChip’s CMO, said:

“It’s valuable for BrainChip to be part of Arm’s portfolio of partners as Arm is not only a leading provider of AI technologies, but an industry influencer. Arm offers us another channel to give end users access to Akida, the world’s first commercial neuromorphic AI accelerator, and to foster the development of best-in-class AI products and applications.”

Global AI in Drug Discovery Market to Reach $9.1B by 2030

Research published by ReportLinker finds that the global AI in Drug Discovery market is projected to reach $9.1 billion USD by 2030, registering a compound annual growth rate (CAGR) of 29.4 percent in the forecast period 2022-30. An excerpt from the report’s description outlines the adoption of AI as a response to the COVID-19 pandemic:

The pandemic has made the adoption of AI more widespread in the pharma industry. AI and its related platforms aim to enhance medical imaging and diagnostics, management of chronic diseases, and drug designing. The overall human hours spent would be far more in comparison to the AI system scanning the same data, which reduces overall cost and is a more feasible approach.

Sam Mowers,

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on visit here

About – News that Inspires Big Investing Ideas publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns: Crypto Corner, Play by Play sports and stock news, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast, Cleantech and Climate Change, Exploring Mining, Betting on Gaming Stocks Podcast and the AI Eye Podcast.

The podcasts are also available on Apple Podcasts, Audible, Spotify, Tunein, Stitcher,, iHeartRadio, Google Podcasts and most audio platforms available.

Visit the Podcast page at

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: Learn more about publishing your news release and our other news services on the newswire Global investors must adhere to regulations of each country. Please read privacy policy:

The AI Eye – Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of

Follow us on Twitter

Follow us on Facebook

Follow us on YouTube


800 665 0411

Buy a technology guest post on

: Two years after George Floyd’s killing, Big Tech shareholders continue racial-justice push

Previous article

Metals Stocks: Gold books 3-day winning streak after notching first weekly gain in a month

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News